Atara Biotherapeutics Inc
ATRA11.355USD
-0.195-1.69%
交易中 （美東）報價延遲15分鐘
67.26M總市值
虧損本益比TTM
關於 Atara Biotherapeutics Inc 公司
Atara Biotherapeutics, Inc. 是一家同種異體 T 細胞免疫療法公司。該公司是 T 細胞免疫療法的開發商，利用其新型同種異體 Epstein-Barr 病毒 (EBV) T 細胞平臺爲患有嚴重疾病（包括實體瘤、血液系統癌症和自身免疫性疾病）的患者開發變革性療法。其產品線包括 Ebvallo (Tab-cel)、ATA3219。該公司的 T 細胞免疫療法 tab-cel (tabelecleucel) 正處於 III 期開發階段，用於治療利妥昔單抗或利妥昔單抗聯合化療失敗的 EBV 驅動的移植後淋巴增生性疾病 (EBV+ PTLD) 患者，以及其他 EBV 驅動的疾病。其 ATA3219 正處於第 1 階段開發，旨在開發一種潛在產品，旨在針對 B 細胞惡性腫瘤和自身免疫性疾病，基於下一代 1XX 共刺激結構域和 EBV T 細胞的先天優勢作爲同種異體 CAR T 平臺的基礎。
公司簡介
公司代碼ATRA
公司名稱Atara Biotherapeutics Inc
上市日期Oct 16, 2014
CEOMr. Anhco (Cokey) Nguyen, Ph.D.
員工數量153
證券類型Ordinary Share
年結日Oct 16
公司地址1280 Rancho Conejo Blvd
城市THOUSAND OAKS
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編91320
電話18056234211
網址https://www.atarabio.com/
公司代碼ATRA
上市日期Oct 16, 2014
CEOMr. Anhco (Cokey) Nguyen, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Pascal Touchon
Dr. Pascal Touchon
Chairman of the Board
Chairman of the Board
46.22K
+20.39%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Dr. Maria Grazia Roncarolo, M.D.
Dr. Maria Grazia Roncarolo, M.D.
Independent Director
Independent Director
11.37K
+221.13%
Mr. Ameet Mallik
Mr. Ameet Mallik
Independent Director
Independent Director
10.93K
+252.52%
Amber Daugherty
Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Mr. Anhco (Cokey) Nguyen, Ph.D.
Mr. Anhco (Cokey) Nguyen, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Ms. Carol G. Gallagher, Pharm.D.
Ms. Carol G. Gallagher, Pharm.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Nachi Subramanian
Mr. Nachi Subramanian
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Pascal Touchon
Dr. Pascal Touchon
Chairman of the Board
Chairman of the Board
46.22K
+20.39%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Director
Independent Director
16.19K
+93.64%
Dr. Maria Grazia Roncarolo, M.D.
Dr. Maria Grazia Roncarolo, M.D.
Independent Director
Independent Director
11.37K
+221.13%
Mr. Ameet Mallik
Mr. Ameet Mallik
Independent Director
Independent Director
10.93K
+252.52%
Amber Daugherty
Amber Daugherty
Senior Director, Strategy and Operations
Senior Director, Strategy and Operations
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Panacea Venture
19.88%
Adiumentum Capital Fund I LP
19.20%
EcoR1 Capital, LLC
8.56%
Redmile Group, LLC
6.60%
The Vanguard Group, Inc.
2.85%
Other
42.91%
持股股東
持股股東
佔比
Panacea Venture
19.88%
Adiumentum Capital Fund I LP
19.20%
EcoR1 Capital, LLC
8.56%
Redmile Group, LLC
6.60%
The Vanguard Group, Inc.
2.85%
Other
42.91%
股東類型
持股股東
佔比
Venture Capital
19.88%
Investment Advisor/Hedge Fund
19.74%
Corporation
19.20%
Investment Advisor
5.52%
Individual Investor
3.21%
Research Firm
3.03%
Hedge Fund
2.87%
Bank and Trust
0.07%
Other
26.48%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
241
4.96M
74.12%
-1.65M
2025Q1
282
4.01M
65.40%
-1.34M
2024Q4
299
3.71M
64.35%
-1.71M
2024Q3
318
3.77M
66.12%
-1.71M
2024Q2
338
3.34M
67.67%
-2.05M
2024Q1
355
3.52M
73.26%
-1.12M
2023Q4
356
2.78M
67.54%
-1.84M
2023Q3
355
3.69M
90.14%
-612.93K
2023Q2
363
3.86M
98.31%
-820.50K
2023Q1
367
4.34M
112.70%
-175.57K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Panacea Venture
1.33M
19.88%
+780.66K
+141.94%
May 16, 2025
Adiumentum Capital Fund I LP
1.28M
19.2%
+151.14K
+13.33%
May 16, 2025
EcoR1 Capital, LLC
573.18K
8.56%
+41.05K
+7.71%
Mar 31, 2025
Redmile Group, LLC
441.70K
6.6%
--
--
May 16, 2025
The Vanguard Group, Inc.
190.76K
2.85%
+11.98K
+6.70%
Mar 31, 2025
BofA Global Research (US)
187.30K
2.8%
-17.87K
-8.71%
Mar 31, 2025
Acadian Asset Management LLC
115.11K
1.72%
-9.36K
-7.52%
Mar 31, 2025
Vestal Point Capital, LP
94.08K
1.41%
-30.91K
-24.73%
Mar 31, 2025
Staley Capital Advisers, Inc.
80.00K
1.2%
+30.00K
+60.00%
Mar 31, 2025
Tang Capital Management, LLC
75.20K
1.12%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
Harbor Human Capital Factor US Small Cap ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Broad Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
Harbor Human Capital Factor US Small Cap ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Schwab U.S. Broad Market ETF
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
公告日期
類型
比率
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
Jun 17, 2024
Merger
25<1
